AR1001 – Biological drug to treat early symptoms of Alzheimer’s Disease

ADUHELM™, also known as BIIB037

$

This study evaluates the safety and effectiveness of AR1001 in Alzheimer’s Disease.

$

This trial will accept new patients soon.

$

The purpose of this study is to find out if an investigational new drug called AR1001 can help people with Alzheimer’s Disease and to see if the drug is safe to be administered in people.

$

Basic Enrollment Criteria:

  • Age 55-80 years old, Male & Female
  • Willing to comply with study visits and requirements
$

Study Length:

  • 56 week treatment phase, 104 week extension phase

Participate In This Study

Sign-up Here